Helicobacter pylori infection
Conditions
Interventions
Group A:Take "Vonoprazan 20mg bid + Amoxicillin 1g tid" for 14 days.
Group B:Classic quadruple therapy (empirical replacement of antibiotics).
Group C:Collect stool specimens for PCR drug resistance gene testing, and provide individualized quadruple therapy based on the results of the drug resistance test.
Sponsors
Northern Jiangsu People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed as Hp positive through 13C-urea breath test who have previously failed to eradicate Hp; 2. More than 6 months since the last eradication of Hp; 3. Understand and be willing to participate in this clinical trial and sign an informed consent form; 4. Age range from 18 to 75 years old (including 18 and 75 years old), regardless of gender; 5. During the period from the time when the subject agreed to be included in the study to the end of the study (that is, the end of the efficacy evaluation visit), it is prohibited to take any antibiotics other than the test drugs or traditional Chinese patent medicines and simple preparations, bismuth agents, acid inhibitors (such as PPI, H2 receptor blockers, P-CAB, etc.) with antibacterial effects.
Exclusion criteria
Exclusion criteria: 1.Individuals with contraindications to penicillin or research protocol related drug allergies; 2.History of gastrectomy; 3.History of gastric malignant tumors, including adenocarcinoma and lymphoma; 4.A history of gastrointestinal diseases with difficulty swallowing or any impact on drug absorption; 5.Individuals with a history of severe central nervous system, cardiovascular, pulmonary, liver, kidney, metabolic, gastrointestinal, urinary, endocrine, and hematological diseases or a history of malignant tumors; 6.Individuals with severe mental illness who cannot cooperate or have communication difficulties; 7.Pregnant, lactating or preparing women; 8.Individuals who have taken bismuth, acid inhibitors, antibiotics, or traditional Chinese medicine with bactericidal effects within the past 4 weeks; 9.Merge other bacterial and viral infections in the past 2 weeks; 10.Participating in other clinical trials; 11.Researchers believe that participants are not suitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The eradication rate of Helicobacter pylori; | — |
Secondary
| Measure | Time frame |
|---|---|
| The rate of adverse reaction incidence;Economic cost; | — |
Countries
China
Contacts
Public ContactLei Chen
Northern Jiangsu People's Hospital
Outcome results
None listed